The abstract is read at the publisher; the summary is JClub's.
Baseline α-synuclein seed amplification assay positivity in the PPMI prodromal Parkinson’s cohort is linked to faster MDS-UPDRS Part III motor progression (0.611 vs 0.139 points/year; P<0.001).
- Why it matters: It addresses whether Syn-SAA reflects not only future phenoconversion but also ongoing motor worsening during the prodromal stage, which remains unclear.
- What they did: Using linear mixed-effects models, the study related baseline Syn-SAA status and kinetic parameters to longitudinal MDS-UPDRS Part III motor, Hoehn and Yahr stage, and MoCA scores, with up to 12 years follow-up.
- The result: The motor association persisted after excluding phenoconverters (0.430 vs 0.202 points/year; P=0.014) and within seven years, and baseline positivity also predicted phenoconversion risk (adjusted hazard ratio 5.72, 95% CI 3.78–8.68; P<0.001).
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.